Literature DB >> 26880419

Differential expression of β-tubulin isotypes in different life stages of Parascaris spp after exposure to thiabendazole.

Eva Tydén1, Moa Skarin2, Mikael Andersson-Franko3, Matilda Sjöblom2, Johan Höglund2.   

Abstract

Anthelmintic resistance (AR) to macrocyclic lactones (ML) has been described in Parascaris of horses world-wide. In contrast, benzimidazoles (BZ) are still effective, although reduced efficacy to this drug class was recently reported. The mode of action of BZ is binding to β-tubulin, which prevents polymerisation of microtubules. In this study, β-tubulin gene expression of isotypes 1 and 2 was investigated at seven time points (0, 6, 24, 72, 96 and 120 h) during embryogenesis and in adult worms. In addition, an in ovo larval developmental test was developed to study β-tubulin gene expression of both isotypes in parasacaris eggs after exposure to different concentrations of thiabendazole (TBZ) for five days at 25 °C. A strong pattern of differential expression of β-tubulin and isotype 1 was observed in all stages, while isotype 2 expression was mainly found at an early phase of the embryogenesis. For isotype 1, a 5-fold increase was observed during the first 48 h, but gene expression gradually decreased after 72, 96 and 120 h. Isotype 2 was only expressed during the first 24h, followed by a 130-fold decrease at (time points) 72, 96 and 120 h. The in ovo larval developmental test, in which we exposed initially unembryonated eggs to increased concentrations of TBZ, did affect isotype 1 gene expression but not isotype 2. This assumes that each isotype has specific functions in different life stages. This is in agreement with the 'multi-tubulin' hypothesis, which states that different tubulin isotypes are required for specialised microtubule functions. Isotype 1 is the most likely drug target for BZs, as isotype 2 was only expressed at very low levels later in development. Increasing concentrations of TBZ altered β-tubulin isotype 1 gene expression after exposure of the eggs for five days, but this was not seen for isotype 2.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Embryogenesis; Gene expression; Life stages; Parascaris spp; Thiabendazole; β-tubulin

Mesh:

Substances:

Year:  2016        PMID: 26880419     DOI: 10.1016/j.molbiopara.2016.02.004

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  5 in total

1.  Reduced efficacy of albendazole against Ascaris lumbricoides in Rwandan schoolchildren.

Authors:  Jürgen Krücken; Kira Fraundorfer; Jean Claude Mugisha; Sabrina Ramünke; Kevin C Sifft; Dominik Geus; Felix Habarugira; Jules Ndoli; Augustin Sendegeya; Caritas Mukampunga; Claude Bayingana; Toni Aebischer; Janina Demeler; Jean Bosco Gahutu; Frank P Mockenhaupt; Georg von Samson-Himmelstjerna
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-06-23       Impact factor: 4.077

2.  Transcriptional responses in Parascaris univalens after in vitro exposure to ivermectin, pyrantel citrate and thiabendazole.

Authors:  Frida Martin; Faruk Dube; Oskar Karlsson Lindsjö; Matthías Eydal; Johan Höglund; Tomas F Bergström; Eva Tydén
Journal:  Parasit Vectors       Date:  2020-07-09       Impact factor: 3.876

Review 3.  The equine ascarids: resuscitating historic model organisms for modern purposes.

Authors:  Jennifer L Cain; Martin K Nielsen
Journal:  Parasitol Res       Date:  2022-08-20       Impact factor: 2.383

4.  Identification of key interactions of benzimidazole resistance-associated amino acid mutations in Ascaris β-tubulins by molecular docking simulations.

Authors:  Ben P Jones; Arnoud H M van Vliet; E James LaCourse; Martha Betson
Journal:  Sci Rep       Date:  2022-08-12       Impact factor: 4.996

5.  Absence of mutations associated with resistance to benzimidazole in the beta-tubulin gene of Ascaris suum.

Authors:  Adalid Palma; Gabriela Matamoros; Denis Escobar; Ana Lourdes Sánchez; Gustavo Fontecha
Journal:  Rev Soc Bras Med Trop       Date:  2020-03-16       Impact factor: 1.581

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.